JADE BIOSCIENCES (JBIO)

What Moves the Stock

1. 1Clinical trial data readouts - primary/secondary endpoint achievement, statistical significance (p-values), safety profile versus placebo/standard-of-care
2. 2FDA regulatory milestones - IND acceptance, Fast Track/Breakthrough Therapy designation, PDUFA date announcements, advisory committee votes
3. 3Capital markets activity - equity offerings, PIPE transactions, debt financing that extend cash runway or signal dilution risk
4. 4Partnership/licensing deals - collaboration announcements with Big Pharma providing validation, upfront payments, and development cost-sharing
5. 5Competitive clinical data - rival programs reporting superior efficacy or safety, potentially obsoleting JBIO's pipeline
6. 6No current revenue - pre-commercial stage
7. 7Future potential: Product sales from lead drug candidate(s) post-FDA approval (estimated 2028-2030+ timeline)
8. 8Potential licensing/partnership milestone payments and royalties from pharma collaborators

JBIO Chart

My Notes

• growth/speculative - Attracts venture capital-style investors seeking asymmetric risk/reward from binary clinical outcomes.
• High sensitivity to interest rate environment through multiple channels: (1) Valuation compression - biotech NPV models are highly…
• Watch on earnings: Clinical trial enrollment velocity and completion timelines versus guidance, Quarterly cash burn rate and remaining runway calculations (cash/quarterly OpEx), 10-year Treasury yield (GS10) as proxy for biotech valuation multiples and financing costs.